Alendronate Sodium Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-26-D-0009

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Piscataway, New Jersey, UNITED STATES

SourceSAM
Documents1
This award notice pertains to the procurement of Alendronate Sodium Tablets, a pharmaceutical product, under contract number SPE2D2-26-D-0009. The award follows a solicitation process initiated under SPE2D2-25-R-0023 and is managed by DLA Troop Support, a federal office within the Defense Logistics Agency (DLA), which operates under the Department of Defense. The primary objective of this procurement is to ensure a reliable supply of Alendronate Sodium Tablets, which are commonly used in the treatment of osteoporosis and related bone conditions, thereby supporting the health and readiness of military personnel and other authorized beneficiaries. The scope of this contract encompasses the manufacturing and delivery of Alendronate Sodium Tablets in accordance with the requirements set forth by DLA Troop Support. The awarded supplier is expected to adhere to stringent quality standards consistent with the NAICS code 325412 (Pharmaceutical Preparation Manufacturing), ensuring that all products meet federal specifications for safety, efficacy, and consistency. The Product Service Code (PSC) associated with this procurement is 6505, which covers drugs and biologicals. The place of performance for this contract is Piscataway, New Jersey, indicating that manufacturing, distribution, or other key contract activities will be based in this location. This centralization supports efficient logistics and supply chain management for the Defense Logistics Agency. Key deliverables under this contract include the timely and compliant production and delivery of Alendronate Sodium Tablets as specified in the contract documentation. The contractor is expected to maintain robust quality assurance processes and comply with all applicable federal regulations throughout the contract lifecycle. The procurement is classified as an award notice, indicating that the contract has already been awarded and is currently active as of March 19, 2026. Interested parties seeking further information or clarification regarding this award may contact the primary point of contact, Courtney Hunter, via email at [email protected]. Secondary contact support is available through Jason Wray at [email protected] or by phone at 445-737-6304. This opportunity is listed on SAM.gov under Opportunity ID ce440910db404ce183a85b975f645953, where additional details and attachments may be available for review. Contractors considering future opportunities in this area should note the federal and defense-specific requirements, the focus on pharmaceutical manufacturing, and the importance of compliance with all relevant standards and regulations. Overall, this contract reflects the Department of Defense’s ongoing commitment to securing high-quality pharmaceutical products for its stakeholders, with DLA Troop Support serving as the central contracting entity responsible for oversight and administration.